S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.45
+1.77
+10.61%
ANTX · AN2 Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
AN2 Therapeutics Inc (ANTX)
NASDAQ NMS - GLOBAL MARKET
Pharmaceuticals
$3.60
+0.03
(+0.84%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$3.60
$3.58
$3.75
52-WEEK RANGE
$3.60
$1.00
$7.19
What's happening
- ANTX is up 0.84% today, trading at $3.60. — Live quote
- Volume today (10,813) is well below its 3-month average of 295,110. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.18 actual vs. $-0.28 estimated (+34.6%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 4
Buy 3
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (8 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
ANTX
+212.28%
vs S&P 500
+199.50%
1-YEAR RETURN
ANTX
+191.80%
vs S&P 500
+177.24%
6-MONTH RETURN
ANTX
+13.38%
3-MONTH RETURN
ANTX
-28.80%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.18
Est. $-0.28
BEAT +34.6%
2026-04-26 (Q1 2026)
$-0.29
Est. $-0.23
MISS -23.6%
2026-01-26 (Q4 2025)
$-0.29
Est. $-0.24
MISS -18.5%
2025-10-26 (Q3 2025)
$-0.31
Est. $-0.22
MISS -38.1%
Valuation Measures & Ratios
Enterprise Value4$91.5M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)—
Price / Book72.30
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-53.52%
Return on Assets (ROA9)-48.64%
Avg Volume (3M)295,110
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $219.9M | $119.5M | $38.6M | $32.5M | $41.7M |
| P/E | -6.46 | -3.27 | -0.98 | -0.73 | -0.77 |
| Price/Book | 2.90 | 1.46 | 0.64 | 0.47 | 0.57 |
| ROE | -44.82% | -44.63% | -64.94% | -64.34% | -74.25% |
| ROA | -41.66% | -41.71% | -58.32% | -58.41% | -66.94% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short2,491,971
Change from Prior Settlement+3.95%
% of Float—
Days to Cover (Short Ratio)9.54
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +191.8%. Finnhub market metrics ↗
Potential concerns
- Latest SEC filing is Form 4, filed 2026-10-13; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on ANTX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$8.9M | -$10.6M | -$10.0M | -$7.2M | -$11.5M | -$14.0M | -$15.9M | -$18.3M |
| Net income | -$8.2M | -$10.0M | -$9.4M | -$6.5M | -$10.6M | -$12.7M | -$14.4M | -$16.6M |
| EPS (diluted) | $-0.18 | $-0.29 | $-0.31 | $-0.21 | $-0.35 | $-0.43 | $-0.48 | $-0.56 |
| EPS (basic) | $-0.18 | $-0.29 | $-0.31 | $-0.21 | $-0.35 | $-0.43 | $-0.48 | $-0.56 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $81.7M | $87.5M | $62.0M | $67.2M | $75.8M | $81.3M | $92.1M | $97.7M |
| Total liabilities | $5.8M | $5.7M | $8.9M | $6.9M | $7.0M | $8.0M | $10.2M | $10.0M |
| Stockholders' equity | $75.9M | $81.8M | $53.1M | $60.4M | $68.8M | $73.3M | $81.8M | $87.7M |
| Total current assets | $80.0M | $87.5M | $59.9M | $64.0M | $67.5M | $69.6M | $86.3M | $97.7M |
| Total current liabilities | $5.6M | $5.6M | $8.7M | — | — | — | $10.2M | $10.0M |
| Cash & equivalents | $44.3M | $53.5M | $19.9M | $18.0M | $18.2M | $20.0M | $21.4M | $33.5M |
| Other non-current assets | $216.0K | — | $0 | $0 | $0 | $304.0K | $804.0K | — |
| Accounts payable | $2.0M | $2.6M | $3.0M | $2.2M | $2.1M | $3.1M | $3.3M | $1.7M |
| Accrued liabilities | $1.7M | $1.8M | $2.1M | $2.7M | $3.0M | $4.0M | $4.5M | $4.9M |
| Other current liabilities | $776.0K | $567.0K | $1.2M | $183.0K | $717.0K | $369.0K | $791.0K | $1.3M |
| Other non-current liabilities | $170.0K | $170.0K | $170.0K | — | — | — | $0 | — |
| Retained earnings | -$259.2M | -$251.0M | -$240.9M | -$232.2M | -$222.9M | -$216.4M | -$205.8M | -$198.3M |
| Accumulated other comprehensive income (loss) | -$23.0K | -$5.0K | $57.0K | $64.0K | $25.0K | $48.0K | $31.0K | $112.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.0M | -$12.1M | -$5.2M | -$6.4M | -$7.6M | -$10.6M | -$5.3M | -$12.0M |
| Investing cash flow | -$3.7M | $8.3M | $7.2M | $6.1M | $5.8M | $9.2M | -$6.9M | $18.7M |
| Financing cash flow | $1.5M | $37.3M | $0 | $48.0K | $0 | $65.0K | $0 | $23.0K |
| Share-based compensation | $972.0K | $1.5M | $1.4M | $801.0K | $2.0M | $2.0M | $1.8M | $1.9M |
| Change in accounts payable | -$998.0K | -$405.0K | $795.0K | $113.0K | -$960.0K | -$244.0K | $1.6M | -$174.0K |
| Purchases of investments | $13.7M | $2.7M | $8.3M | $3.9M | $11.7M | $22.3M | $24.4M | $9.8M |
| Sales/maturities of investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$38.1M | -$56.8M | -$69.6M | -$42.3M | -$21.6M |
| Net income | -$35.2M | -$51.3M | -$64.7M | -$41.0M | -$21.5M |
| EPS (diluted) | $-1.16 | $-1.72 | $-2.74 | $-2.79 | $-10.64 |
| EPS (basic) | $-1.16 | $-1.72 | $-2.74 | $-2.79 | $-10.64 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $62.0M | $92.1M | $138.7M | $102.6M | $65.3M |
| Total liabilities | $8.9M | $10.2M | $14.0M | $7.2M | $3.4M |
| Stockholders' equity | $53.1M | $81.8M | $124.7M | $95.4M | -$47.4M |
| Total current assets | $59.9M | $86.3M | $110.5M | $98.6M | $60.1M |
| Total current liabilities | $8.7M | $10.2M | $14.0M | $7.2M | $3.4M |
| Cash & equivalents | $19.9M | $21.4M | $15.6M | $27.2M | $12.1M |
| Other non-current assets | $0 | $804.0K | $1.0M | $720.0K | — |
| Accounts payable | $3.0M | $3.3M | $2.7M | $2.1M | $1.1M |
| Accrued liabilities | $2.1M | $4.5M | $6.7M | $2.8M | $1.4M |
| Other current liabilities | $1.2M | $791.0K | $666.0K | — | — |
| Other non-current liabilities | $170.0K | $0 | — | — | — |
| Retained earnings | -$240.9M | -$205.8M | -$154.5M | -$89.7M | -$47.4M |
| Accumulated other comprehensive income (loss) | $57.0K | $31.0K | $275.0K | -$374.0K | -$27.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$29.8M | -$49.3M | -$53.3M | -$33.5M | -$20.5M |
| Investing cash flow | $28.3M | $54.6M | -$43.3M | -$21.8M | -$50.0M |
| Financing cash flow | $113.0K | $372.0K | $85.0M | $70.4M | $78.5M |
| Share-based compensation | $6.2M | $8.3M | $8.4M | $4.4M | $974.0K |
| Change in accounts payable | -$296.0K | $641.0K | $553.0K | $2.5M | $417.0K |
| Purchases of investments | $46.2M | $46.8M | $132.2M | $93.8M | $77.3M |
| Sales/maturities of investments | $0 | $0 | $0 | $0 | $0 |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding ANTX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-04-10 to 2026-10-12
Recent transactions
- Insiders have net sold 57,013 shares over the last 182 days, across 1 purchase and 11 sales.
- Most recent: Marks Gilbert Lynn (Reporting person) — Grant / award of 2,283 shares on 2026-10-12.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)2,098 sh(1 txns)
Sales (open market)59,111 sh(11 txns)
Net Shares-57,013
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Marks Gilbert Lynn | Reporting person | Grant / award | 2026-10-12 | 2,283 |
| Martin Patricia A. | Reporting person | Grant / award | 2026-10-12 | 389 |
| Aziz Kabeer | Reporting person | Grant / award | 2026-10-12 | 2,465 |
| Trenor Cameron C. III | Chief Medical Officer | Grant / award | 2026-09-15 | 116,667 |
| Readnour Robin Shane | Reporting person | Open market sale | 2026-09-09 | 523 |
| Williams Sarah Joanne | Principal Accounting Officer | Open market sale | 2026-09-01 | 272 |
| FitzPatrick Margaret M | Reporting person | Open market purchase | 2026-09-01 | 2,098 |
| Zakrzewski Joseph S | Reporting person | Gift | 2026-08-14 | 405,880 |
| Eizen Joshua M | See Remarks | Open market sale | 2026-07-08 | 5,945 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-12 | Marks Gilbert Lynn | Reporting person | Grant / award | 2,283 | $0.00 |
| 2026-10-12 | Martin Patricia A. | Reporting person | Grant / award | 389 | $0.00 |
| 2026-10-12 | Aziz Kabeer | Reporting person | Grant / award | 2,465 | $0.00 |
| 2026-09-15 | Trenor Cameron C. III | Chief Medical Officer | Grant / award | 116,667 | $0.00 |
| 2026-09-09 | Readnour Robin Shane | Reporting person | Open market sale | 523 | $6.02 |
| 2026-09-09 | Readnour Robin Shane | Reporting person | Open market sale | 585 | $6.02 |
| 2026-09-08 | Readnour Robin Shane | Reporting person | Open market sale | 4,725 | $6.02 |
| 2026-09-08 | Readnour Robin Shane | Reporting person | Open market sale | 5,294 | $6.02 |
| 2026-09-03 | Readnour Robin Shane | Reporting person | Open market sale | 2,877 | $6.07 |
| 2026-09-03 | Readnour Robin Shane | Reporting person | Open market sale | 3,223 | $6.07 |
| 2026-09-01 | Williams Sarah Joanne | Principal Accounting Officer | Open market sale | 272 | $5.53 |
| 2026-09-01 | FitzPatrick Margaret M | Reporting person | Open market purchase | 2,098 | $5.53 |
| 2026-08-17 | Readnour Robin Shane | Reporting person | Open market sale | 16,696 | $6.01 |
| 2026-08-17 | Readnour Robin Shane | Reporting person | Open market sale | 18,706 | $6.01 |
| 2026-08-14 | Zakrzewski Joseph S | Reporting person | Gift | 405,880 | $0.00 |
| 2026-07-10 | Aziz Kabeer | Reporting person | Grant / award | 2,852 | $0.00 |
| 2026-07-10 | Marks Gilbert Lynn | Reporting person | Grant / award | 2,789 | $0.00 |
| 2026-07-10 | Martin Patricia A. | Reporting person | Grant / award | 766 | $0.00 |
| 2026-07-08 | Eizen Joshua M | See Remarks | Open market sale | 5,945 | $4.17 |
| 2026-05-29 | Williams Sarah Joanne | Principal Accounting Officer | Open market sale | 265 | $4.43 |
| 2026-04-10 | Aziz Kabeer | Reporting person | Grant / award | 3,775 | $0.00 |
| 2026-04-10 | Marks Gilbert Lynn | Reporting person | Grant / award | 3,775 | $0.00 |
| 2026-04-10 | Martin Patricia A. | Reporting person | Grant / award | 1,192 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 08:36 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-13 | 4 | 2026-10-12 | View on SEC.gov → |
| 2026-10-13 | 4 | 2026-10-12 | View on SEC.gov → |
| 2026-10-13 | 4 | 2026-10-12 | View on SEC.gov → |
| 2026-09-16 | 4 | 2026-09-15 | View on SEC.gov → |
| 2026-09-11 | 4 | 2026-09-09 | View on SEC.gov → |
| 2026-09-08 | 4 | 2026-09-03 | View on SEC.gov → |
| 2026-09-04 | 4 | 2026-09-01 | View on SEC.gov → |
| 2026-09-02 | 4 | 2026-09-01 | View on SEC.gov → |
| 2026-08-19 | 4 | 2026-08-17 | View on SEC.gov → |
| 2026-08-14 | 4 | 2026-08-14 | View on SEC.gov → |
| 2026-08-11 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-11 | 8-K | 2026-08-11 | View on SEC.gov → |
Recent news
Headlines about ANTX (AN2 Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms
Yahoo · 2026-10-21 -
AN2 Therapeutics to Participate at Upcoming Investor Conferences
Yahoo · 2026-10-20 -
ANTX Oct 2026 4.000 put (ANTX261016P00004000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-16 -
GSK (LSE:GSK) Deepens Its Drug Pipeline Through Two Research Partnerships
Yahoo · 2026-10-08 -
GSK (LSE:GSK) The Latest Update Raises A Bigger Question
Yahoo Finance · 2026-09-30 -
AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK
Yahoo Finance · 2026-09-28 -
AN2 Therapeutics: A Failed Drug Could Become A Major Value Driver
Seeking Alpha · 2026-09-22 -
AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)
Yahoo Finance · 2026-09-16
No headlines in this category right now — try “All”.